ABOLERIS PHARMA, AN EMERGING COMPANY IN THE FIELD OF IMMUNOTHERAPY RESEARCH ESTABLISHED ON 28th NOVEMBER 2019, DEVELOPS PROPRIETARY MOLECULES THAT INHIBIT THE IMMUNE RESPONSE IN PATIENTS.
The principle, already patented in several countries, involves adjusting the balance between the regulatory and effector T cells involved in the immune response.
Supported by its promising lab results, the company is now seeking sponsors to finance the preliminary stages of its development by initiating the regulatory preclinical study phase on its first product. The company’s research activities recently benefited from a maturation fund from SATT Ouest Valorisation.
Partnerships with the pharmaceutical industry should enable ABOLERIS PHARMA to offer treatment solutions in the medium to long-term, with a focus on fighting autoimmune diseases, increasing organ transplantation tolerance and managing graft-versus-host diseases.
The company, championed by ATLANPOLE since December 2015, is run by François-Xavier Hubert, supported by two co-founding scientists: Carole Guillonneau and Ignacio Anegon, from the joint research centre (INSERM, Nantes University) CRTI – Centre for Research into Organ Transplantation and Immunology. Aboleris Pharma is aligned with the historical “immunotherapies” focus at the Grand Ouest Atlanpole Biotherapies competitive cluster (https://www.atlanpolebiotherapies.com/immunobiotherapie/) and plays an important role in building up the region’s industrial skills base.